Immutep Ltd · ASX:IMM
Immutep — Shareholder Meeting (November 2022)
22 slides from Immutep's shareholder meeting presentation, Nov 23, 2022
Slide 1: A Global Leader in LAG-3 Therapeutics in Oncology and Autoimmune Disease
For personal use only A Global Leader in LAG-3 Therapeutics in Oncology and Autoimmune Disease AGM Presentation – November 2022 (ASX: IMM, NASDAQ: IMMP)
Slide 2: Forward-Looking Statements
Forward-Looking Statements For personal use only The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanat
Slide 3: Immutep Overview
Immutep Overview For personal use only Pioneering LAG-3 Portfolio Collaborations with Industry Leaders in Oncology & Autoimmune Disease Immutep is a pure-play LAG-3 clinical-stage company with four product candidates that address significant market opportunities in oncology & autoimmune disease Comp
Slide 4: LAG-3: Approved Checkpoint with Unique Characteristics
LAG-3: Approved Checkpoint with Unique Characteristics For personal use only Immune system’s role in controlling cancer has led to regulatory approval of immunotherapies targeting CTLA-4, PD-1, and now LAG-3 checkpoints Cytotoxic T lymphocyte Programmed Cell Death Lymphocyte Activating Antigen-4 (CT
Slide 5: Immutep Pipeline Update
For personal use only Immutep Pipeline Update
Slide 6: Immutep LAG-3 Pipeline
Immutep LAG-3 Pipeline For personal use only Program Preclinical Phase I Phase II Late Stage* Commercial Rights Metastatic Breast Cancer (Chemo-IO) - AIPAC 1st Line Head and Neck Squamous Cell Carcinoma (IO-IO) - TACTI-003a Eftilagimod Alpha (efti or IMP321) 2nd Line Head and Neck Squamous Cell Carc
Slide 7: Multiple Companies Targeting LAG-3 Inhibition
Multiple Companies Targeting LAG-3 Inhibition For personal use only Releasing the Brake on T cells Company* Program Phase 1 Phase 2 Phase 3 8 35 4 Received FDA approval Relatlimab in March 2022 Blocking LAG-3 / MHC II interaction increases Favezelimab 1 8 1 cytotoxicity of pre-existing CD8 T cell re
Slide 8: Efti: First-in-Class Positioning in LAG-3 Oncology Landscape
Efti: First-in-Class Positioning in LAG-3 Oncology Landscape For personal use only Pushing the Accelerator on the Immune System APC activation with Efti Anti-tumor immune cell activation Serum Biomarkers Eftilagimod alpha (Efti) Efti APC LAG-3 MHC II Dendritic Cells T-cells NK Cells Monocytes IFN-ƴ
Slide 9: LAG-3 Leadership
LAG-3 Leadership For personal use only Immutep has more LAG-3 product candidates in development than any other biotech or big pharmaceutical company Efti data selected for SITC 2022 Press Conference Immutep’s late-breaking abstract for 1st line non-small cell lung cancer patients from Phase II TACTI
Slide 10: Benchmarking against Pembrolizumab Monotherapy
Benchmarking against Pembrolizumab Monotherapy: Strong ORR/PFS Across Entire PD-L1 Spectrum vs Pembrolizumab TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) For personal use only Key Takeaways Overall Response Rate* (ORR) Median Progression Free Survival# (PFS) (with 95% confidence interval) (by PD-L1 TPS
Slide 11: Deep and Durable Responses
Deep and Durable Responses TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) For personal use only 2, 3 Tumor Burden Reduced in Majority of Patients Interim Median Duration of Response (DoR) 100 100 DoR by iRECIST (N=40) (%) (%) 75 90 80 Events, n (%) 10 (25.0) Response Best % change from baseline 50 70 Medi
Slide 12: IO + IO + Chemo Combination Trial (INSIGHT-003)
IO + IO + Chemo Combination Trial (INSIGHT-003) INSIGHT-003: Phase I in Solid Tumors Focusing on NSCLC Adenocarcinomas For personal use only INSIGHT-003 - Third arm (Stratum C) of ongoing investigator- Initial Efficacy Tumour Response according to RECIST 1.1 (N=11) N, (%) initiated study focusing on
Slide 13: 2L HNSCC: Robust ORR/CR with Long-Lasting Efficacy
2L HNSCC: Robust ORR/CR with Long-Lasting Efficacy TACTI-002/KEYNOTE-798: 2nd Line Head & Neck Squamous Cell Carcinoma (Part C) For personal use only Responses at all PD-L1 levels including 5 iCRs Efti + Keytruda Keytruda Combination* Monotherapy# Best % change from baseline Clinical Trial & Phase P
Slide 14: Targeting 1L HNSCC with Fast Track Designation (TACTI-003)
Targeting 1L HNSCC with Fast Track Designation (TACTI-003) TACTI-003: Phase IIb in 1st Line Head and Neck Squamous Cell Carcinoma (HNSCC) For personal use only Design: • Randomised trial with ORR as primary endpoint • Sites worldwide (AU, US, Europe) • Approximately 154 patients: either to be random
Slide 15: AIPAC Phase IIb: Driving OS Improvement with Superior QoL
AIPAC Phase IIb: Driving OS Improvement with Superior QoL AIPAC: Active Immunotherapy PAClitaxel in HER2–/ HR+ metastatic breast cancer Phase IIb Trial For personal use only Statistically-Significant Increase of AIPAC: Multicenter, placebo-controlled, double-blind, Cytotoxic CD8+ T Cell Count Statis
Slide 16: Clinical Development Strategy for Efti
Clinical Development Strategy for Efti For personal use only Encouraging clinical data supports broad therapeutic potential of efti - optionality to progress development in multiple indications. Prioritising 1st line Ongoing development Future development in Continued NSCLC in 1st line HNSCC metasta
Slide 17: IMP761: Broad Potential Targeting Auto-Reactive Memory T Cells
IMP761: Broad Potential Targeting Auto-Reactive Memory T Cells For personal use only Deficiency in LAG3 Pathways Linked to IMP761 Immutep’s proprietary humanized IgG4 Development of Autoimmune Diseases (AI) LAG-3–specific antibody A LAG -3–Specific Agonist Antibody for the Treatment of T Cell –Induc
Slide 18: Novel Small Molecule Anti-LAG-3 Collaboration
Novel Small Molecule Anti-LAG-3 Collaboration For personal use only Collaboration established in 2019 combining Immutep’s deep LAG-3 biology experience and expertise of world leading scientists at Cardiff University “We are delighted to collaborate with Immutep on this important project to develop a
Slide 19: Key Financials
Key Financials For personal use only FY22 FY21 Revenue and other income increased mainly due the Revenue and other income A$6.8M A$4.0M recognition of a net gain in FX of A$1.2M and an increase in R&D tax rebates. A$4.5M from the Australian and French G&A Expenses A$7.2M A$6.3M governments was recog
Slide 20: Milestones ahead
Milestones ahead For personal use only 2022 2023 • Year to date:* • TACTI-003 updates and top line readout 1L NSCLC Oral Presentation at ASCO (TACTI-002; Part A) • TACTI-002 data updates 2L NSCLC PD-X refractory data at ELCC & WCLC 2022 (TACTI-002; Part B) • INSIGHT-003 updates and readout Fas
Slide 21: Corporate Snapshot
Corporate Snapshot For personal use only Pioneering LAG-3 portfolio in oncology and autoimmune diseases with four product candidates in multiple clinical trials Analyst research coverage • First-in-class positioning with eftilagimod alpha (efti) • Multiple big pharma partnerships & collaborations, w
Slide 22: Thank You
For personal use only Thank You